Wall Street Zen Upgrades Tyra Biosciences (NASDAQ:TYRA) to “Hold”

Tyra Biosciences (NASDAQ:TYRA) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other research firms have also recently issued reports on TYRA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Saturday, September 27th. Oppenheimer reiterated an “outperform” rating and set a $36.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, September 10th. Raymond James Financial began coverage on shares of Tyra Biosciences in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Tyra Biosciences presently has an average rating of “Moderate Buy” and an average price target of $31.86.

Tyra Biosciences Trading Up 2.0%

Shares of NASDAQ:TYRA opened at $13.66 on Friday. The firm has a 50 day moving average of $11.92 and a 200-day moving average of $10.46. The stock has a market capitalization of $728.04 million, a PE ratio of -7.67 and a beta of 1.11. Tyra Biosciences has a 12 month low of $6.42 and a 12 month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.06. On average, research analysts predict that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Institutional Trading of Tyra Biosciences

Large investors have recently modified their holdings of the stock. Two Sigma Advisers LP acquired a new stake in shares of Tyra Biosciences during the 4th quarter worth approximately $171,000. Bank of America Corp DE raised its position in shares of Tyra Biosciences by 21.7% during the fourth quarter. Bank of America Corp DE now owns 66,157 shares of the company’s stock worth $920,000 after purchasing an additional 11,804 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Tyra Biosciences by 23.6% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 301,801 shares of the company’s stock worth $2,807,000 after purchasing an additional 57,556 shares in the last quarter. Polar Asset Management Partners Inc. lifted its holdings in shares of Tyra Biosciences by 27.1% in the 1st quarter. Polar Asset Management Partners Inc. now owns 141,241 shares of the company’s stock worth $1,314,000 after purchasing an additional 30,134 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its position in Tyra Biosciences by 42.7% in the 1st quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company’s stock valued at $110,000 after purchasing an additional 3,550 shares during the period. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.